Leerink Partners Downgrades Compass Therapeutics (CMPX) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

November 15, 2024 7:05 AM EST
Get Alerts CMPX Hot Sheet
Price: $2.25 -0.44%

Rating Summary:
    16 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE

Leerink Partners analyst Andrew Berens downgraded Compass Therapeutics (NASDAQ: CMPX) from Outperform to Market Perform with a price target of $4.00 (from $5.00).


For an analyst ratings summary and ratings history on Compass Therapeutics click here. For more ratings news on Compass Therapeutics click here.


Shares of Compass Therapeutics closed at $1.59 yesterday.


You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades